207 related articles for article (PubMed ID: 32860347)
1. Dihydrotanshinone I inhibits ovarian cancer cell proliferation and migration by transcriptional repression of PIK3CA gene.
Wang X; Xu X; Jiang G; Zhang C; Liu L; Kang J; Wang J; Owusu L; Zhou L; Zhang L; Li W
J Cell Mol Med; 2020 Oct; 24(19):11177-11187. PubMed ID: 32860347
[TBL] [Abstract][Full Text] [Related]
2. Dihydrotanshinone-I modulates Epithelial Mesenchymal Transition (EMT) Thereby Impairing Migration and Clonogenicity of Triple Negative Breast Cancer Cells.
Kashyap A; Umar SM; Dev J R A; Prasad CP
Asian Pac J Cancer Prev; 2021 Jul; 22(7):2177-2184. PubMed ID: 34319041
[TBL] [Abstract][Full Text] [Related]
3. HPIP promotes epithelial-mesenchymal transition and cisplatin resistance in ovarian cancer cells through PI3K/AKT pathway activation.
Bugide S; Gonugunta VK; Penugurti V; Malisetty VL; Vadlamudi RK; Manavathi B
Cell Oncol (Dordr); 2017 Apr; 40(2):133-144. PubMed ID: 28039608
[TBL] [Abstract][Full Text] [Related]
4. 15,16-dihydrotanshinone I inhibits EOMA cells proliferation by interfering in posttranscriptional processing of hypoxia-inducible factor 1.
Duan P; Huang Y; Chen K; Cheng C; Wu Z; Wu Y
Int J Med Sci; 2021; 18(14):3214-3223. PubMed ID: 34400891
[TBL] [Abstract][Full Text] [Related]
5. Dual PI3K/mTOR inhibitor PKI-402 suppresses the growth of ovarian cancer cells by degradation of Mcl-1 through autophagy.
Hu X; Xia M; Wang J; Yu H; Chai J; Zhang Z; Sun Y; Su J; Sun L
Biomed Pharmacother; 2020 Sep; 129():110397. PubMed ID: 32585451
[TBL] [Abstract][Full Text] [Related]
6. Gemcitabine as a molecular targeting agent that blocks the Akt cascade in platinum-resistant ovarian cancer.
Kawaguchi H; Terai Y; Tanabe A; Sasaki H; Takai M; Fujiwara S; Ashihara K; Tanaka Y; Tanaka T; Tsunetoh S; Kanemura M; Ohmichi M
J Ovarian Res; 2014 Apr; 7():38. PubMed ID: 24713296
[TBL] [Abstract][Full Text] [Related]
7. The PI3K/AKT/mTOR pathway is a potential predictor of distinct invasive and migratory capacities in human ovarian cancer cell lines.
Bai H; Li H; Li W; Gui T; Yang J; Cao D; Shen K
Oncotarget; 2015 Sep; 6(28):25520-32. PubMed ID: 26267321
[TBL] [Abstract][Full Text] [Related]
8. MiR-337-3p suppresses proliferation of epithelial ovarian cancer by targeting PIK3CA and PIK3CB.
Zhang Z; Zhang L; Wang B; Wei R; Wang Y; Wan J; Zhang C; Zhao L; Zhu X; Zhang Y; Chu C; Guo Q; Yin X; Li X
Cancer Lett; 2020 Jan; 469():54-67. PubMed ID: 31629932
[TBL] [Abstract][Full Text] [Related]
9. Bufalin inhibits ovarian carcinoma via targeting mTOR/HIF-α pathway.
Su S; Dou H; Wang Z; Zhang Q
Basic Clin Pharmacol Toxicol; 2021 Feb; 128(2):224-233. PubMed ID: 32905663
[TBL] [Abstract][Full Text] [Related]
10. Downregulation of miR-503 contributes to the development of drug resistance in ovarian cancer by targeting PI3K p85.
Wu D; Lu P; Mi X; Miao J
Arch Gynecol Obstet; 2018 Mar; 297(3):699-707. PubMed ID: 29327155
[TBL] [Abstract][Full Text] [Related]
11. MicroRNA-302 represses epithelial-mesenchymal transition and cisplatin resistance by regulating ATAD2 in ovarian carcinoma.
Ge T; Liu T; Guo L; Chen Z; Lou G
Exp Cell Res; 2020 Nov; 396(1):112241. PubMed ID: 32835657
[TBL] [Abstract][Full Text] [Related]
12. Sanguinarine inhibits epithelial ovarian cancer development via regulating long non-coding RNA CASC2-EIF4A3 axis and/or inhibiting NF-κB signaling or PI3K/AKT/mTOR pathway.
Zhang S; Leng T; Zhang Q; Zhao Q; Nie X; Yang L
Biomed Pharmacother; 2018 Jun; 102():302-308. PubMed ID: 29571014
[TBL] [Abstract][Full Text] [Related]
13. MiRNAs and their interplay with PI3K/AKT/mTOR pathway in ovarian cancer cells: a potential role in platinum resistance.
Gasparri ML; Besharat ZM; Farooqi AA; Khalid S; Taghavi K; Besharat RA; Sabato C; Papadia A; Panici PB; Mueller MD; Ferretti E
J Cancer Res Clin Oncol; 2018 Dec; 144(12):2313-2318. PubMed ID: 30109500
[TBL] [Abstract][Full Text] [Related]
14. The effects of REG4 expression on chemoresistance of ovarian cancer.
Xiang LW; Xue H; Ha MW; Yu DY; Xiao LJ; Zheng HC
J Obstet Gynaecol; 2022 Oct; 42(7):3149-3157. PubMed ID: 35929918
[TBL] [Abstract][Full Text] [Related]
15. Metabolic reprogramming in colon cancer reversed by DHTS through regulating PTEN/AKT/HIF1α mediated signal pathway.
Wang L; Yu Z; Ren S; Song J; Wang J; Du G
Biochim Biophys Acta Gen Subj; 2018 Oct; 1862(10):2281-2292. PubMed ID: 30036603
[TBL] [Abstract][Full Text] [Related]
16. Lysine demethylase 2A promotes the progression of ovarian cancer by regulating the PI3K pathway and reversing epithelial‑mesenchymal transition.
Lu DH; Yang J; Gao LK; Min J; Tang JM; Hu M; Li Y; Li ST; Chen J; Hong L
Oncol Rep; 2019 Feb; 41(2):917-927. PubMed ID: 30483796
[TBL] [Abstract][Full Text] [Related]
17. Cisplatin triggers cancer stem cell enrichment in platinum-resistant cells through NF-κB-TNFα-PIK3CA loop.
Thakur B; Ray P
J Exp Clin Cancer Res; 2017 Nov; 36(1):164. PubMed ID: 29169370
[TBL] [Abstract][Full Text] [Related]
18. SMAD3 inducing the transcription of STYK1 to promote the EMT process and improve the tolerance of ovarian carcinoma cells to paclitaxel.
Shi Y; Zhang J; Liu M; Huang Y; Yin L
J Cell Biochem; 2019 Jun; 120(6):10796-10811. PubMed ID: 30701575
[TBL] [Abstract][Full Text] [Related]
19. Resveratrol Contrasts LPA-Induced Ovarian Cancer Cell Migration and Platinum Resistance by Rescuing Hedgehog-Mediated Autophagy.
Ferraresi A; Esposito A; Girone C; Vallino L; Salwa A; Ghezzi I; Thongchot S; Vidoni C; Dhanasekaran DN; Isidoro C
Cells; 2021 Nov; 10(11):. PubMed ID: 34831435
[No Abstract] [Full Text] [Related]
20. CHD4 regulates platinum sensitivity through MDR1 expression in ovarian cancer: A potential role of CHD4 inhibition as a combination therapy with platinum agents.
Oyama Y; Shigeta S; Tokunaga H; Tsuji K; Ishibashi M; Shibuya Y; Shimada M; Yasuda J; Yaegashi N
PLoS One; 2021; 16(6):e0251079. PubMed ID: 34161330
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
